EVEROLIMUS MSDS PDF

Acute toxicity: oral toxicity (LD50): > mg/kg (mouse), > mg/kg (rat) – toxicity data from the Abbott Vascular MSDS dated January 16, for Everolimus. SAFETY DATA SHEET. (in accordance with Regulation (EU) /). Everolimus. Version: 1. Revision date: 29/06/ Page 1 of. Material Safety Data Sheet. Section 1 – Product and Company Information. Product Name: Everolimus. Cat. Code: tlrl-eve. Company identification: InvivoGen.

Author: Gardatilar Akinoktilar
Country: Uganda
Language: English (Spanish)
Genre: Photos
Published (Last): 4 February 2006
Pages: 295
PDF File Size: 14.9 Mb
ePub File Size: 7.60 Mb
ISBN: 365-6-37525-977-2
Downloads: 88362
Price: Free* [*Free Regsitration Required]
Uploader: Vilmaran

Dolutegravir The serum concentration of Dolutegravir can be increased when it is combined with Everolimus. Mercaptopurine The risk or severity of adverse effects can be increased when Mercaptopurine is combined with Everolimus. Lisuride The metabolism of Everolimus can be decreased when combined with Lisuride. Lenalidomide The risk or severity of adverse effects can be increased when Lenalidomide is combined with Everolimus. Gusperimus The risk or severity of adverse effects can be increased when Everolimus is combined with Gusperimus.

Levothyroxine The metabolism of Levothyroxine can be decreased when combined with Everolimus. Nystatin The metabolism of Everolimus can be decreased when combined with Nystatin. Patupilone The metabolism of Everolimus can be decreased when combined with Patupilone. Clorindione The metabolism of Clorindione can be decreased when combined with Everolimus. Dofequidar The serum concentration of Everolimus can be increased when it is combined with Dofequidar.

  BOGENBAU ANLEITUNG PDF

Basiliximab The risk or severity of adverse effects can be increased when Basiliximab is combined with Everolimus. Brotizolam The metabolism of Everolimus can be decreased when combined with Brotizolam. Doxepin The serum concentration of Everolimus can be increased when it is combined with Doxepin.

everoliums The complex then binds to mTOR preventing it from interacting with target proteins. Peginterferon beta-1a The risk or severity of adverse effects can be increased when Everolimus is combined with Peginterferon beta-1a.

Cymarin The serum concentration of Cymarin can be increased when it is combined with Everolimus. Penicillamine The risk or severity of adverse effects can be increased when Penicillamine is combined with Everolimus.

Amodiaquine The serum concentration of Everolimus can be increased when it is combined with Amodiaquine. Lamivudine The serum concentration of Lamivudine can be increased when it is combined with Everolimus. Antilymphocyte immunoglobulin horse The evfrolimus or severity of adverse effects can be increased when Everolimus is combined with Antilymphocyte immunoglobulin horse. Biricodar dicitrate The serum concentration of Everolimus can be increased when it is combined with Biricodar dicitrate.

Everolimus

Gliquidone The therapeutic efficacy of Gliquidone can be decreased when used in combination with Everolimus. Metformin The therapeutic efficacy of Metformin can be decreased when used in combination with Everolimus.

  DERMATITIS NUMULAR PDF

Erlotinib The serum concentration of Everolimus can be increased when it is combined with Erlotinib.

Duvelisib The metabolism of Everolimus can be decreased when combined with Duvelisib. Ethynodiol diacetate The metabolism of Everolimus can be decreased when combined eferolimus Ethynodiol diacetate.

Guanethidine The metabolism of Everolimus can be increased when combined with Guanethidine. Norethisterone The metabolism of Everolimus can be decreased when combined with Norethisterone. Palifermin The therapeutic efficacy of Palifermin can be decreased when used in combination with Everolimus. Benzylpenicillin The excretion of Benzylpenicillin can be decreased when combined with Everolimus.

Everolimus – DrugBank

Flurazepam The serum concentration of Everolimus can be increased when it is combined with Flurazepam. Carbomycin The metabolism of Everolimus can be decreased when combined with Carbomycin. Alprazolam The serum concentration of Alprazolam can be increased when it is combined with Everolimus.

Estramustine The serum concentration of Everolimus can be increased when it is combined with Estramustine. Macrolide immunosuppressant; derivative of Rapamycin. Deferasirox The metabolism of Everolimus can be increased when combined with Deferasirox.

Edoxaban The serum concentration of Edoxaban can be increased when it is combined with Everolimus.